Eurofins Scientific SE (ERF) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Eurofins Scientific SE stock €68.19, price €87.24, that is 21.8% below the price, quality 59 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range €42.73 – €118.49 · fair‑value band €35.39 – €88.65 · the €87.24 price screens above the €68.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Eurofins Scientific in your weekly email
Every Wednesday you see whether Eurofins Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Show moreShow less
It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics.
The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services.
In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing.
Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
Stock analysis
Eurofins Scientific SE (ERF) currently trades at €87.24, while our model-based Fair Value estimate is €68.19, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €79.83 per share, and 5 of the 24 models we run sit above the €87.24 price.
Bear case: the Dividend Discount group reads lowest at €10.77, and 19 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: €35.39 (bear) to €88.65 (bull), the price of €87.24 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Eurofins Scientific SE reported revenue of €7.3B in FY2025 versus €6.7B in FY2021, a compound +2.1%/yr. Reported net income was €475M in FY2025, compounding −11.7%/yr from FY2021.
Key figures
Market cap €16.0B Large · P/E ratio 30.3 · P/S ratio 2.21 · EPS (TTM) €2.88 · Dividend yield 0.8% · Net margin 7.2% · Return on equity 11.3% · Return on assets (EBIT) 8.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −22%, ERF screens richer than that median.
Fair Value models
Bear€35.39Fair Value €68.19Bull€88.65
Price €87.24 · Downside -21.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€1.85 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +14.1% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−0.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.6%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.6% vs 16.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +16.8% a year for the price and +2.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (56 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
AI conclusion: The established hub-and-spoke laboratory network in bioanalytical services forms the main strength, while thin evidence of a durable moat together with elevated leverage remains the central weakness.
Main risk: An FDA warning letter for incomplete records and selective reporting at a contract microbiology lab could lead to heightened regulatory scrutiny, remediation costs or loss of customer confidence in Eurofins' bioanalytical testing services.
Bull case: Strengthened quality systems and transparent remediation could enhance Eurofins' reputation for reliability and attract more regulated clients seeking compliant partners.
Bear case: Persistent compliance issues might result in further FDA actions, restricted operations or customers shifting to alternative testing providers with stronger records.
Eurofins has completed the divestment of its electrical and electronics testing business alongside the acquisition of a North American life sciences testing portfolio. The moves tighten the company's emphasis on bioanalytical services within its established hub-and-spoke laboratory network. Will the added North American capacity and freed capital accelerate growth more than the ongoing weakness in certain biopharma activities holds it back?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−23.1% · Above median
Profitability
Return on equity (12 months)11.3% · Above median
Return on assets4.3% · Above median
Net margin (12 months)7.2% · Above median
Operating margin (12 months)16.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)2.5% · Below median
Dividend yield (12 months)0.8% · Below median
Balance sheet
Debt / equity0.96× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)30.3× · Cheaper than median
P/B4.60× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.21× · Cheaper than median
Price / free cash flow (fiscal year)30.4× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Eurofins Scientific SE Fair Value". https://www.fairvalue-calculator.com/stock/ERF
Frequently asked questions
Is Eurofins Scientific SE (ERF) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €68.19 versus a price of €87.24, about 22% lower (overvalued).
What is the fair value of ERF?
Our model-based fair value for Eurofins Scientific SE is €68.19 (as of Nov 9, 2026), built from audited fundamentals. The current price: €87.24.
What is the quality score of ERF?
Eurofins Scientific SE has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eurofins Scientific SE (ERF)?
Our model-based price target is the fair value of €68.19 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario €35.39, optimistic scenario €88.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Eurofins Scientific SE stock forecast for 2026?
Our models put fair value at €68.19, about 22% lower versus a price of €87.24 (overvalued). Cautious scenario €35.39, optimistic scenario €88.65. The calculation is refreshed regularly with new filings.
What is the revenue of Eurofins Scientific SE (ERF)?
Eurofins Scientific SE reported trailing-twelve-month revenue of about €7.4B (latest available figure, as of Nov 9, 2026).
Does Eurofins Scientific SE pay a dividend?
Eurofins Scientific SE currently shows a dividend yield of 0.83% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Eurofins Scientific SE (ERF) and when is the ex-dividend date?
Eurofins Scientific SE pays a dividend of €0.72 per share a year, a dividend yield of 0.8%. The last ex-dividend date was Apr 28, 2026. A dividend has been paid every year since 2021. The payout ratio is 25.0% of earnings. Free cash flow covers the dividend 4.34 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Eurofins Scientific SE (ERF)?
For today's price to be fair in a discounted-cash-flow model, Eurofins Scientific SE would have to grow free cash flow by +19.4 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of ERF use?
Our models discount Eurofins Scientific SE at 9.3 %: a base by market capitalisation (large), damped by beta 0.81, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eurofins Scientific SE that is +19.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Eurofins Scientific SE (ERF) delivered so far?
Over the past 5 years revenue at Eurofins Scientific SE grew +6.1 % a year. The price currently implies free-cash-flow growth of +19.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eurofins Scientific SE (ERF) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Eurofins Scientific SE (+19.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eurofins Scientific SE (ERF)?
The free-cash-flow yield on the price is 3.34 %: that much free cash flow Eurofins Scientific SE produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eurofins Scientific SE (ERF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eurofins Scientific SE it is €68.19 per share (as of Nov 9, 2026), against a price of €87.24. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Eurofins Scientific SE stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ERF trades above its calculated fair value: price €87.24, fair value €68.19, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERF?
No. The price is what the market pays today (€87.24); the fair value is what the company's own numbers justify (€68.19). For Eurofins Scientific SE the two are €19.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eurofins Scientific SE worth?
The market values Eurofins Scientific SE at about €16.0B (market capitalisation, as of Nov 9, 2026). Per share that is €87.24; our models calculate a fair value of €68.19 per share.
What do the bullish and bearish scenarios say about ERF?
Our models span a range for Eurofins Scientific SE: cautious scenario €35.39, base €68.19, optimistic €88.65 per share (as of Nov 9, 2026, price €87.24). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ERF?
Eurofins Scientific SE trades at a price-to-earnings ratio of 30.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €68.19 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 24.8. Other multiples: PEG 0.9, P/B 4.6, P/S 2.2, EV/EBITDA 12.3.
What is the PEG ratio of ERF?
The PEG ratio of Eurofins Scientific SE is 0.92 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Eurofins Scientific SE (ERF)?
Balance-sheet figures for Eurofins Scientific SE (as of Nov 9, 2026): return on equity 11.3%, debt of 0.96 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is ERF from its 52-week high?
Eurofins Scientific SE trades at €87.24, about 2% below its 52-week high of €89.04 and 56% above the low of €56.08 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €68.19 is for.
Which stocks are comparable to Eurofins Scientific SE?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eurofins Scientific SE stock attractive at the current price?
The data as of Nov 9, 2026: price €87.24, calculated fair value €68.19 (−22%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ERF calculated?
We run Eurofins Scientific SE through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €68.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Eurofins Scientific SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eurofins Scientific SE (ERF)?
The closing price on Nov 9, 2026 was €87.24. Our model-based fair value is €68.19, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eurofins Scientific SE right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€35.39 to €88.65) leaves room in how you read the outcome.
Where does the earnings growth of Eurofins Scientific SE (ERF) come from?
Earnings per share at Eurofins Scientific SE grew +12.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.0 %, EBIT margin +1.4 %, tax rate +0.1 %, residual (interest, one-offs) −1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Eurofins Scientific SE
How large is the market capitalisation of Eurofins Scientific SE (ERF)?
The market capitalisation of Eurofins Scientific SE is €16.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eurofins Scientific SE (ERF)?
The price-to-sales ratio of Eurofins Scientific SE is 2.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eurofins Scientific SE (ERF)?
Earnings per share at Eurofins Scientific SE are €2.88 (price ÷ EPS = P/E 30.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Eurofins Scientific SE (ERF)?
The dividend yield of Eurofins Scientific SE is 0.8% (payout 25.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Eurofins Scientific SE (ERF)?
The net margin of Eurofins Scientific SE is 7.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eurofins Scientific SE (ERF)?
The return on equity (ROE) of Eurofins Scientific SE is 11.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eurofins Scientific SE (ERF)?
On an EBIT basis the return on assets of Eurofins Scientific SE is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eurofins Scientific SE (ERF)?
The operating margin of Eurofins Scientific SE is 16.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eurofins Scientific SE (ERF)?
Revenue at Eurofins Scientific SE is growing +2.5% versus a year earlier (3y avg +2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eurofins Scientific SE (ERF)?
Earnings per share at Eurofins Scientific SE are growing +28.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Eurofins Scientific SE (ERF) carry?
The net debt of Eurofins Scientific SE is €4.6B (fiscal year 2025, ≈ 8.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Eurofins Scientific SE in the live analysis
One click puts Eurofins Scientific SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026